Studying Takayasu's arteritis that affects the lung arteries
Looks at the features, treatment and long-term outcomes in adults with lung artery involvement.
Plain-language title generated from the registry record
Registry title: Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- China-Japan Friendship HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT07184814
- Record updated
- 22 September 2025
- Original description
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).Read full original descriptionShow less
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
Inclusion: Hospitalized between Jan 1, 2016 and Dec 31, 2026; Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria; Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography; Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion.
Exclusion: Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension.